Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fresolimumab and Stereotactic Ablative Radiotherapy in Early Stage Non-small Cell Lung Cancer

NCT02581787 is registered in ClinicalTrials.gov with Maximilian Diehn as lead sponsor.

NCT NCT02581787
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02581787 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fresolimumab and Stereotactic Ablative Radiotherapy in Early Stage Non-small Cell Lung Cancer
Lead sponsor
Maximilian Diehn
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2016
Completion date
March 2, 2023
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage ia non-small cell lung carcinoma, stage ib non-small cell lung carcinoma